Compounds for treating cancer

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is hydrogen, cyano, C3-C6 cycloalkyl, C1-C6 alkyl optionally substituted with phenyl optionally substituted with halogen, C1-C6 thioalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkoxyalkyl;
• R1′ is hydrogen or C1-C6 alkyl;
• or R1 and R1′, together with the carbon atom to which they are attached form a C3-C10 cycloalkyl;
• R2 is C6-C12 aryl optionally substituted with 1-4 independently selected R2A, 5-10 membered heteroaryl optionally substituted with 1-4 independently selected R2A, 4-10 membered heterocyclyl optionally substituted with 1-4 independently selected R2A, C4-C10 cycloalkyl optionally substituted with 1-4 independently selected R2A, C1-C6 alkoxyalkyl optionally substituted with —C(═O)NRARC, C1-C6 aralkyl optionally substituted with 1-4 independently selected R2A, or C1-C6 alkoxy optionally substituted with —C(═O)NRARC;
• each R2A is independently selected from:
• (i) halogen,
• (ii) cyano,
• (iii) hydroxyl,
• (iv) —NRARB,
• (v) —C(═O)NRARB,
• (vii) —NHC(═O)RC,
• (viii) —C(═O)RD,
• (ix) —C(═O)ORE,
• (x) —SO2RF,
• (xi) —NHSO2RF,
• (xii) —SO2NRFRG,
• (xiii) —NHC(═O)C1-C6 alkyl optionally substituted with NRARB,
• (xiv) C1-C6 haloalkyl,
• (xv) C1-C6 hydroxyalkyl,
• (xvi) 5-10 membered heteroaryl optionally substituted with 1-3 substituents independently selected from C1-C6 alkyl, —C(═O)NRARB, C1-C6 haloalkyl, and —NRARB,
• (xvii) 4-10 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from hydroxyl, C1-C6 haloalkyl, —C(═O)C1-C6 alkyl, —SO2(C1-C6 alkyl), —SO2NRFRG, C6-C12 aryl, C1-C6 alkyl optionally substituted with C1-C6 alkoxy, —C(═O)NRARB, or —NHC(═O)C1-C6 alkyl optionally substituted with —NRARB,
• (xviii) C1-C6 alkyl optionally substituted with 1-3 substituents independently selected from hydroxyl, oxo, —NRARB, —C(═O)NRARB, C1-C6 alkoxy, C3-C10 cycloalkyl, phenyl, and 4-10 membered heterocyclyl optionally substituted with hydroxyl, C1-C6 alkyl, aralkyl, heteroaralkyl, —C(═O)NRARB, or —C(═O)C3-C6 cycloalkyl,
• (xix) C1-C6 alkoxy optionally substituted with —NRARB or 4-10 membered heterocyclyl optionally substituted with C1-C6 alkyl, hydroxyl, aralkyl, heteroaralkyl, or —C(═O)C3-C6 cycloalkyl,
• (xx) C3-C6 cycloalkyl optionally substituted with 4-10 membered heterocyclyl optionally substituted with C1-C6 alkyl;
• (xxi) C6-C12 aryl optionally substituted with 1-3 substituents independently selected from hydroxyl, cyano, C1-C6 haloalkyl, —ORE, —C(═O)C1-C6 alkyl, —SO2(C1-C6 alkyl), —SO2NRFRG, 4-10 membered heterocyclyl, or C1-C6 alkyl optionally substituted with C1-C6 alkoxy, hydroxyl, or —C(═O)NRARB;
• and
• (xxii) 4-10 membered heterocyclyloxy optionally substituted with 1-3 substituents independently selected from hydroxyl, C1-C6 haloalkyl, —C(═O)C1-C6 alkyl, —SO2(C1-C6 alkyl), —SO2NRFRG, C6-C12 aryl, C1-C6 alkyl optionally substituted with C1-C6 alkoxy, —C(═O)NRARB, or —NHC(═O)C1-C6 alkyl optionally substituted with —NRARB;
• each RA and RB is independently selected from hydrogen, hydroxyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C2-C6 alkenyl, cyano, 4-10 membered heterocyclyl, and C1-C6 alkyl optionally substituted with hydroxyl or C1-C6 alkoxy, or RA and RB together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclyl optionally substituted with 1-2 substituents independently selected from halogen, hydroxyl, C1-C6 alkyl, and —C(═O)C1-C6 alkyl;
• each RC is independently selected from C3-C6 cycloalkyl, —C(═O)NHRY1, C2-C6 alkenyl, or a C1-C6 alkyl optionally substituted with —NRARB or with 4-10 membered heterocyclyl optionally substituted with C1-C6 alkyl or with C1-C6 hydroxylalkyl;
• each RD and RE is independently selected from hydrogen, hydroxyl, C1-C6 alkyl, phenyl, 4-10 membered heterocyclyl, —NRARB, C1-C6 alkoxy, and C3-C6 cycloalkyl, wherein the C1-C6 alkyl, 4-10 membered heterocyclyl, and phenyl are optionally substituted with 4-10 membered heterocyclyl, C3-C6 cycloalkyl, or cyano, and the C3-C6 cycloalkyl is optionally substituted with C1-C6 alkyl optionally substituted with hydroxyl or C1-C6 alkoxy;
• each R3A and R3B is independently selected from hydrogen C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 haloalkyl, or R3A and R3B, together with the carbon and nitrogen atoms, respectively, to which they are attached together form a 4-8 membered heterocyclyl group;
• R4 is hydrogen, C1-C6 alkyl, or acrylamido;
• R5 is hydrogen, C1-C6 alkyl, halogen, C1-C6 haloalkyl, C3-C6 cycloalkyl, cyano, —NR5AR5B, —NR5AC(═O)R5B, or —C(═O)NR5AR5B;
• R5A and R5B are independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, and C1-C6 hydroxyalkyl;
• R6 is hydrogen, halogen, or C1-C6 alkyl;
• X is a bond, CH2, CH(CH3), C(CH3)2, or
• Y is phenyl optionally substituted with 1-3 independently selected RY, naphthyl optionally substituted with 1-3 independently selected RY, or 5-10 membered heteroaryl optionally substituted with 1-3 independently selected RY;
• each RY is independently selected from:
• halogen, cyano, hydroxyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 hydroxyalkyl, —NHC(═O)RC, —C(═O)NHR, —CO2RA, —SO2NRFRG, —NHSO2RF, —S(═O)(═NRF)RG, —SO2(C1-C6 alkyl), —C(═O)NRARB, 5-6 membered heteroaryl, heteroaralkyl, and C1-C6 alkyl optionally substituted with —CO2RA or 5-6 membered heteroaryl optionally substituted with RY1;
• RY1 is —SO2(C1-C6 alkyl), hydroxyl, or C1-C6 alkyl optionally substituted with oxo;
• and
• each RF and RG is independently selected from hydrogen, phenyl, and C1-C6 alkyl optionally substituted with oxo or —NRARB.